ARON 3D_Transparent

Publications

All our publications
mRNA ARON 1

mRNA expression, tumor heterogeneity, and response to therapy inpatients with advanced renal cell carcinoma treated with immune-basedcombinations (ARON-1α)

Aguzzi C
et al. Biochem Biophys Rep.
2025
nivo cabo 1

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

Bourlon MT
et al. Front Oncol
2025
non clear

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell RenalCell Carcinoma: Results from the ARON-1 Study

Massari F
, et al. Eur Urol Focus
2025
Cabo nivo vs pembro axi 1

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients withmetastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Santoni M
Cancer Immunol Immunother.
2025
Geo diff

Geographical Differences in the Management and Outcomes of PatientsWith Advanced Urothelial Carcinoma Treated With Pembrolizumab AfterProgression on Platinum-Based Chemotherapy: Results From ARON-2Study

Rizzo M,
JCO Glob Oncol.
2025
MOUSEION 010

Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis

Vitale E
et al. Immunotherapy
2025

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.